Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
Robert I. Haddad(Georgetown University), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Nicholas J. Sarlis(Incyte (United States)), Sewanti Limaye(Dana-Farber Cancer Institute), Jonathan J. Beitler(Emory University), Guilherme Rabinowits(Baptist Hospital of Miami), Fadlo R. Khuri(American University of Beirut Medical Center), Douglas R. Adkins(Washington University in St. Louis), Roy B. Tishler(Dana-Farber Cancer Institute), Sarah Riley(Dana-Farber Cancer Institute), Jochen H. Lorch(Northwestern University), Anne O’Neill(International Breast Cancer Study Group), Joseph I. Clark(Loyola University Medical Center)
Cited by 748
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926